Market revenue in 2023 | USD 30.4 million |
Market revenue in 2030 | USD 48.8 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Regulatory writing & publishing |
Fastest growing segment | Legal Representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
Key market players worldwide | Genpact Ltd, Icon PLC, Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Drug Development, Cencora Inc, Pharmexon, QVigilance, Voisin Consulting Life Sciences, Accell, Criterium Inc., Freyr Solutions, PharmaLex, NDA Regulatory Service GmbH, BlueReg Group, Cambridge Regulatory Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 31.58% in 2023. Horizon Databook has segmented the UAE biopharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Currently, UAE is the third largest market for pharmaceutical regulatory affairs in the MEA, as most market players depend on imports. Medical device regulations in the country are based on Australian TGA, EU, and the U.S. regulations. The products approved by the Canadian, Australian, EU, and the U.S. regulatory agencies are eligible for a short registration process in the UAE.
The UAE government is focused on attracting innovative drug manufacturers by 2021, with double the number of local companies producing patented drugs. The country has a short drug registration system for innovator and generic drugs approved by the U.S. FDA.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE biopharmaceutical regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into UAE biopharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account